trending Market Intelligence /marketintelligence/en/news-insights/trending/Oe7xzPRPZXMmt5mIp1f_pQ2 content esgSubNav
In This List

Li Kang Biomedical Q3 profit climbs 16.5% YOY


HDFC Securities Investment Research Now Available through S&P Capital IQ Pro


MediaTalk | Season 2
Ep.2 Back to the Box Office


The Marriage of Two Best-in-Class Solutions Delivers a Significant Advancement in Data Visualization and Technical Analysis

Case Study

A Green Lender Adopts a Robust Approach for Assessing Project Finance Credit Risks

Li Kang Biomedical Q3 profit climbs 16.5% YOY

Li Kang Biomedical Co. Ltd. said its third-quarter normalized net income came to 25 Taiwan cents per share, a gain of 16.4% from 22 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$5.6 million, a gain of 16.5% from NT$4.8 million in the prior-year period.

The normalized profit margin climbed to 5.9% from 5.1% in the year-earlier period.

Total revenue totaled NT$94.8 million, compared with NT$93.9 million in the year-earlier period, and total operating expenses fell year over year to NT$85.2 million from NT$87.6 million.

Reported net income rose 14.3% year over year to NT$8.9 million, or 40 cents per share, from NT$7.8 million, or 35 cents per share.

As of Nov. 11, US$1 was equivalent to NT$31.93.